Improving hospice care for patients with blood cancers
HEME-Hospice: An Intervention to improve Hospice Use for Patients with Hematologic Malignancies
['FUNDING_R37'] · DANA-FARBER CANCER INST · NIH-11089554
This study is working to improve hospice care for adults with blood cancers by creating a new program that allows them to get important blood transfusions at home, so they can enjoy better end-of-life care in a comfortable and familiar setting.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11089554 on ClinicalTrials.gov |
What this research studies
This research aims to enhance hospice care for adults with blood cancers, who often miss out on its benefits. It addresses the barriers that prevent these patients from accessing hospice services, particularly the lack of blood transfusion options. By developing a new model of hospice care called HEME-Hospice, the project seeks to integrate necessary transfusions into home-based hospice settings, allowing patients to receive quality end-of-life care in a familiar environment. The approach includes input from patients and caregivers to ensure it meets their needs effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with blood cancers who are nearing the end of life and require hospice care.
Not a fit: Patients with non-cancer-related terminal illnesses or those who do not have blood cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the quality of life for patients with blood cancers during their end-of-life care.
How similar studies have performed: Previous research has shown that integrating specialized care models can improve outcomes for patients in hospice, suggesting that this approach may also be effective.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ODEJIDE, OREOFE OLUKEMI — DANA-FARBER CANCER INST
- Study coordinator: ODEJIDE, OREOFE OLUKEMI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: blood cancer, Cancer Center